The potential of mesenchymal stem cell therapy for chronic lung disease

References

• Weiss DJ, Bates JHT, Gilbert T, et al. Stem cells and cell therapies in lung biology and diseases: conference report. Ann Am Thorac Soc. 2013;10:S25–44.
   PubMedGoogle Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;1900164.
   Google Scholar
• Weiss DJ. Concise review: current status of stem cells and regenerative medicine in lung biology and diseases. Stem Cells. 2014;32:16–25.
   PubMed Web of Science ®Google Scholar
• Kotton DN. Next Generation Regeneration: the Hope and Hype of Lung Stem Cell Research. Am J Respir Crit Care Med. 2012;12:1255–1260.
   Google Scholar
• Wecht S, Rojas M. Mesenchymal stem cells in the treatment of chronic lung disease. Respirology. 2016;21:1366–1375.
   PubMedGoogle Scholar
• Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med. 2017;61:1445–1451.
   Google Scholar
• Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019;8:1609206.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315–317.
   PubMed Web of Science ®Google Scholar
• Cai SX, Liu AR, Chen S, et al. Activation of Wnt/beta-catenin signalling promotes mesenchymal stem cells to repair injured alveolar epithelium induced by lipopolysaccharide in mice. Stem Cell Res Ther. 2015;6:65.
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20:14–20.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12:383–396.
   PubMed Web of Science ®Google Scholar
• Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther. 2016;7:7.
   PubMed Web of Science ®Google Scholar
• Cruz FF, Rocco PRM. Stem-cell extracellular vesicles and lung repair. Stem Cell Inv. 2017;4:78.
   PubMedGoogle Scholar
• Akram KM, Samad S, Spiteri MA, et al. Mesenchymal stem cells promote alveolar epithelial cell wound repair in vitro through distinct migratory and paracrine mechanisms. Respir Res. 2013;14:9.
   PubMed Web of Science ®Google Scholar
• Fang X, Neyrinck AP, Matthay MA, et al. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin 1. J Biol Chem. 2010;285:26211–26222.
   PubMed Web of Science ®Google Scholar
• Paliwal S, Chaudhuri R, Agrawal A, et al. Regenerative abilities of mesenchymal stem cells through mitochondrial transfer. J Biomed Sci. 2018;25:31.
   PubMed Web of Science ®Google Scholar
• Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012;18:759–765.
   PubMed Web of Science ®Google Scholar
• Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial activity of mesenchymal stem cells: current status and new perspectives of antimicrobial peptide-based therapies. Front Immunol. 2017;8:339.
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13:392–402.
   PubMed Web of Science ®Google Scholar
• Srour N, Thébaud B. Mesenchymal stromal cells in animal bleomycin pulmonary fibrosis models: a systematic review. Stem Cells Transl Med. 2015;4:1500–1510.
   PubMed Web of Science ®Google Scholar
• The Global Initiative for Asthma. GINA Report, Global Strategy for Asthma Management and Prevention. 2019.
   Google Scholar
• Goodwin M, Sueblinvong V, Eisenhauer P, et al. Bone marrow derived mesenchymal stromal cells inhibit Th2-mediated allergic airways inflammation in mice. Stem Cells. 2011;29:1137–1148.
   PubMed Web of Science ®Google Scholar
• de Castro LL, Xisto DG, Kitoko JZ, et al. Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma. Stem Cell Res Ther. 2017;8:151.
   PubMed Web of Science ®Google Scholar
• Abreu SC, Antunes MA, Xisto DG, et al. Bone marrow, adipose, and lung tissue‐derived murine mesenchymal stromal cells release different mediators and differentially affect airway and lung parenchyma in experimental asthma. Stem Cells Transl Med. 2017;6:1557–1567.
   PubMed Web of Science ®Google Scholar
• Kitoko JZ, Nascimento AP, Abreu SC, et al. Therapeutic administration of bone marrow‐derived mesenchymal stromal cells reduces airway inflammation without upregulating Tregs in experimental asthma. Clin Exp Allergy. 2018;48:205–216.
   PubMed Web of Science ®Google Scholar
• Abreu SC, Lopes-Pacheco MS, Da Silva AL, et al. Eicosapentaenoic acid enhances the effects of mesenchymal stromal cell therapy in experimental allergic asthma. Front Immunol. 2018;9:1147.
   PubMed Web of Science ®Google Scholar
• Abreu SC, Xisto DG, de Oliveira TB, et al. Serum from asthmatic mice potentiates the therapeutic effects of mesenchymal stromal cells in experimental allergic asthma. Stem Cells Transl Med. 2019;8:301–312.
   PubMed Web of Science ®Google Scholar
• Lathrop MJ, Brooks EM, Bonenfant NR, et al. Mesenchymal stromal cells mediate aspergillus hyphal extract-induced allergic airways inflammation by inhibition of the Th17 signaling pathway. Stem Cells Transl Med. 2014;3:194–205.
   PubMed Web of Science ®Google Scholar
• Cruz FF, Rocco PRM, Weiss DJ. hMSCs as an alternative therapeutic option for asthma with neutrophil mediated inflammation. Exp Mol Med. 2018;50:72.
   PubMed Web of Science ®Google Scholar
• Cruz FF, Borg ZD, Goodwin M, et al. Systemic administration of human bone marrow-derived mesenchymal stromal cell extracellular vesicles ameliorates aspergillus hyphal extract-induced allergic airway inflammation in immunocompetent mice. Stem Cells Transl Med. 2015;4:1302–1316.
   PubMed Web of Science ®Google Scholar
• Cruz FF, Borg ZD, Goodwin M, et al. Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airway inflammation in immunocompetent mice. Stem Cells Transl Med. 2015;6:615–624.
   Google Scholar
• Cruz FF, Borg ZD, Goodwin M, et al. CD11b+ and Sca-1+ cells exert the main beneficial effects of systemically administered bone marrow-derived mononuclear cells in a murine model of mixed Th2/Th17 allergic airway inflammation. Stem Cells Transl Med. 2016;4:488–499.
   Google Scholar
• Ionescu LI, Alphonse RS, Arizmendi N, et al. Airway delivery of soluble factors from plastic-adherent bone marrow cells prevents murine asthma. Am J Respir Cell Mol Biol. 2012;46:207–216.
   PubMed Web of Science ®Google Scholar
• de Castro LL, Lopes-Pacheco M, Weiss DJ, et al. Current understanding of the immunosuppressive properties of mesenchymal stromal cells. J Mol Med (Berl). 2019;97:605–618.
   PubMed Web of Science ®Google Scholar
• Abreu SC, Antunes MA, de Castro JC, et al. Bone marrow-derived mononuclear cells vs. mesenchymal stromal cells in experimental allergic asthma. Respir Physiol Neurobiol. 2013;187:190–198.
   PubMed Web of Science ®Google Scholar
• Aguiar FS, Melo AS, Araujo AMS, et al. Bone marrow-derived mononuclear cell therapy in a patient with severe asthma: a case report. Am J Respir Crit Care Med. 2017;195:A5320.
   Web of Science ®Google Scholar
• Liu X, Fang Q, Kim H. Preclinical Studies of Mesenchymal Stem Cell (MSC) Administration in Chronic Obstructive Pulmonary Disease (COPD): a systematic review and meta-analysis. PLoS One. 2016;11:e0157099.
   PubMed Web of Science ®Google Scholar
• Ma N, Gai H, Mei J, et al. Bone marrow mesenchymal stem cells can differentiate into type II alveolar epithelial cells in vitro. Cell Biol Int. 2011;35:1261–1266.
   PubMed Web of Science ®Google Scholar
• Liu A, Chen S, Cai S, et al. Wnt5a through noncanonical Wnt/JNK or Wnt/PKC signaling contributes to the differentiation of mesenchymal stem cells into type II alveolar epithelial cells in vitro. PLoS One. 2014;9:e90229.
   PubMed Web of Science ®Google Scholar
• Liu AR, Liu L, Chen S, et al. Activation of canonical wnt pathway promotes differentiation of mouse bone marrow-derived MSCs into type II alveolar epithelial cells, confers resistance to oxidative stress, and promotes their migration to injured lung tissue in vitro. J Cell Physiol. 2013;228:1270–1283.
   PubMed Web of Science ®Google Scholar
• Huang K, Kang X, Wang X, et al. Conversion of bone marrow mesenchymal stem cells into type II alveolar epithelial cells reduces pulmonary fibrosis by decreasing oxidative stress in rats. Mol Med Rep. 2015;11:1685–1692.
   PubMed Web of Science ®Google Scholar
• Loi R, Beckett T, Goncz KK, et al. Limited restoration of cystic fibrosis lung epithelium in vivo with adult bone marrow-derived cells. Am J Respir Crit Care Med. 2006;173:171–179.
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim JY, Shin DM, et al. Tracking intravenous adipose-derived mesenchymal stem cells in a model of elastase-induced emphysema. Tuberc Respir Dis (Seoul). 2014;77:116–123.
   PubMedGoogle Scholar
• Huh JW, Kim SY, Lee JH, et al. Bone marrow cells repair cigarette smoke-induced emphysema in rats. Am J Physiol Lung Cell Mol Physiol. 2011;301:L255–66.
   PubMed Web of Science ®Google Scholar
• Schweitzer KS, Johnstone BH, Garrison J, et al. Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med. 2011;183:215–225.
   PubMed Web of Science ®Google Scholar
• Guan XJ, Song L, Han FF, et al. Mesenchymal stem cells protect cigarette smoke-damaged lung and pulmonary function partly via VEGF-VEGF receptors. J Cell Biochem. 2013;114:323–335.
   PubMed Web of Science ®Google Scholar
• Hong Y, Kim YS, Hong SH, et al. Therapeutic effects of adipose-derived stem cells pretreated with pioglitazone in an emphysema mouse model. Exp Mol Med. 2016;48:e266.
   PubMed Web of Science ®Google Scholar
• Ingenito EP, Tsai L, Murthy S, et al. Autologous lung-derived mesenchymal stem cell transplantation in experimental emphysema. Cell Transplant. 2012;21:175–189.
   PubMed Web of Science ®Google Scholar
• Antunes MA, Abreu SC, Cruz FF, et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema. Respir Res. 2014;15:118.
   PubMed Web of Science ®Google Scholar
• Zhen G, Liu H, Gu N, et al. Mesenchymal stem cells transplantation protects against rat pulmonary emphysema. Front Biosci. 2008;13:3415–3422.
   PubMed Web of Science ®Google Scholar
• Gu W, Song L, Li XM, et al. Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways. Sci Rep. 2015;5:8733.
   PubMed Web of Science ®Google Scholar
• Furuya N, Takenaga M, Ohta Y, et al. Cell therapy with adipose tissue-derived stem/stromal cells for elastase-induced pulmonary emphysema in rats. Regen Med. 2012;7:503–512.
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee JH, Kim HJ, et al. Mesenchymal stem cell-conditioned media recovers lung fibroblasts from cigarette smoke-induced damage. Am J Physiol Lung Cell Mol Physiol. 2012;302:L891–99.
   PubMed Web of Science ®Google Scholar
• Katsha AM, Ohkouchi S, Xin H, et al. Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther. 2011;19:196–203.
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim JY, Cho R, et al. Adipose stem cell-derived nanovesicles inhibit emphysema primarily via an FGF2-dependent pathway. Exp Mol Med. 2017;49:e284.
   PubMed Web of Science ®Google Scholar
• Théry C, Amigorena S, Raposo G, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. In Wiley Online Library. Cur Protoc Cell Biol. 2006. Vol. 30. Chapter 3:Unit3.22: 3.22.1–3.22.29.
   PubMedGoogle Scholar
• Ribeiro-Paes JT, Bilaqui A, Greco OT, et al. Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema. Int J Chron Obstruct Pulmon Dis. 2011;6:63–71.
   PubMed Web of Science ®Google Scholar
• Stessuk T, Ruiz MA, Greco OT, et al. Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years. Rev Bras Hematol Hemoter. 2013;35:352–357.
   PubMedGoogle Scholar
• Weiss DJ, Casaburi R, Flannery R, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143:1590–1598.
   PubMed Web of Science ®Google Scholar
• de Oliveira HG, Cruz FF, Antunes MA, et al. Combined bone marrow-derived mesenchymal stromal cell therapy and one-way endobronchial valve placement in patients with pulmonary emphysema: a phase i clinical trial. Stem Cells Transl Med. 2017;6(3):962–969.
   PubMed Web of Science ®Google Scholar
• Stolk J, Broekman W, Mauad T, et al. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM. 2016;109:331–336.
   PubMed Web of Science ®Google Scholar
• Francois M, Copland IB, Yuan S, et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy. 2012;14:147–152.
   PubMed Web of Science ®Google Scholar
• Beane OS, Fonseca VC, Cooper LL, et al. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One. 2014;9:e115963.
   PubMed Web of Science ®Google Scholar
• Bustos ML, Huleihel L, Kapetanaki MG, et al. Aging mesenchymal stem cells fail to protect because of impaired migration and anti-inflammatory response. Am J Respir Crit Care Med. 2014;189:787–798.
   PubMed Web of Science ®Google Scholar
• Broekman W, Roelofs H, Zarcone MC, et al. Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients. ERJ Open Res. 2016;2:00045–2015.
   PubMedGoogle Scholar
• Sun Z, Li F, Zhou X, et al. Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials. J Thorac Dis. 2018;10:1084–1098.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
   PubMed Web of Science ®Google Scholar
• Hostettler KE, Gazdhar A, Khan P, et al. Multipotent mesenchymal stem cells in lung fibrosis. PloS One. 2017;12:e0181946.
   PubMed Web of Science ®Google Scholar
• Tan JL, Lau SN, Leaw B, et al. Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair. Stem Cells Transl Med. 2018;7:180–196.
   PubMed Web of Science ®Google Scholar
• Choi M, Ban T, Rhim T. Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of microvesicle released from mesenchymal stem cell. Mol Cells. 2014;37:133–139.
   PubMed Web of Science ®Google Scholar
• Shentu TP, Wong S, Espinoza C, et al. Extracellular vesicles isolated from human mesenchymal stem cells promote resolution of pulmonary fibrosis. Faseb J. 2016;30:160.2.
   Web of Science ®Google Scholar
• Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase i safety clinical trial. Chest. 2017;151(5):971–981.
   PubMed Web of Science ®Google Scholar
• Zhang C, Yin X, Zhang J, et al. Clinical observation of umbilical cord mesenchymal stem cell treatment of severe idiopathic pulmonary fibrosis: A case report. Exp Ther Med. 2017;13:1922–1926.
   PubMed Web of Science ®Google Scholar
• Chuang HM, Shih TE, Lu KY, et al. Mesenchymal stem cell therapy of pulmonary fibrosis: improvement with target combination. Cell Transplant. 2018;27:1581–1587.
   Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–818.
   PubMed Web of Science ®Google Scholar
• de Mendonça L, Felix NS, Blanco NG, et al. Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. Stem Cell Res Ther. 2017;8:220.
   PubMed Web of Science ®Google Scholar
• Takemiya K, Kai H, Yasukawa H, et al. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol. 2010;105:409–417.
   PubMed Web of Science ®Google Scholar
• Liang OD, Mitsialis SA, Chang MS, et al. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells. 2011;29:99–107.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Fang Z, Hu X, et al. MicroRNAs and mesenchymal stem cells: hope for pulmonary hypertension. Rev Bras Cir Cardiovasc. 2015;30:380–385.
   PubMedGoogle Scholar
• Baber SR, Deng W, Master RG, et al. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2007;292(2):H1120–8.
   PubMed Web of Science ®Google Scholar
• Aslam M, Baveja R, Liang OD, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med. 2009;180:1122–1130.
   PubMed Web of Science ®Google Scholar
• Spees JL, Whitney MJ, Sullivan DE, et al. Bone marrow progenitor cells contribute to repair and remodeling of the lung and heart in a rat model of progressive pulmonary hypertension. Faseb J. 2008;22:1226–1236.
   PubMed Web of Science ®Google Scholar
• Umar S, de Visser YP, Steendijk P, et al. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009;297:H1606–16.
   PubMed Web of Science ®Google Scholar
• Kanki-Horimoto S, Horimoto H, Mieno S, et al. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation. 2006;114(1 Suppl):I181–5.
   PubMedGoogle Scholar
• Hansmann G, Fernandez-Gonzalez A, Aslam M, et al. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circul. 2012;2(2):170–181.
   PubMedGoogle Scholar
• Aliotta JM, Pereira M, Wen S, et al. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice. Cardiovasc Res. 2016;110:319–330.
   PubMed Web of Science ®Google Scholar
• Chen JY, An R, Liu ZJ, et al. Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats. Acta Pharmacol Sin. 2014;35:1121–1128.
   PubMed Web of Science ®Google Scholar
• Wang XX, Zhang FR, Shang YP, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol. 2007;49:1566–1571.
   PubMed Web of Science ®Google Scholar
• Zhu JH, Wang XX, Zhang FR, et al. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr Transplant. 2008;12:650–655.
   PubMed Web of Science ®Google Scholar
• Granton J, Langleben D, Kutryk MB, et al. Endothelial NO-synthase gene-enhanced progenitor cell therapy for pulmonary arterial hypertension: the PHACeT trial. Circ Res. 2015;117:645–654.
   PubMed Web of Science ®Google Scholar
• Middleton RC, Fournier M, Xu X, et al. Therapeutic benefits of intravenous cardiosphere-derived cell therapy in rats with pulmonary hypertension. PLoS One. 2017;12:e0183557.
   PubMed Web of Science ®Google Scholar
• Sato T, Shimosato T, Klinman DM. Silicosis and lung cancer: current perspectives. Lung Cancer (Auckl). 2018;9:91–101.
   PubMed Web of Science ®Google Scholar
• Lassance RMR, Prota LFM, Maron-Gutierrez T, et al. Intratracheal instillation of bone marrow-derived cell in an experimental model of silicosis. Resp Physiol Neurobiol. 2009;169:227–233.
   PubMed Web of Science ®Google Scholar
• Maron-Gutierrez T, Castiglione RC, Xisto DG, et al. Bone marrow-derived mononuclear cell therapy attenuates silica-induced lung fibrosis. Eur Respir J. 2011;37:1217–1225.
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Xisto DG, Ornellas FM, et al. Repeated administration of bone marrow-derived cells prevents disease progression in experimental silicosis. Cell Physiol Biochem. 2013;32:1681–1694.
   PubMedGoogle Scholar
• Zhao MM, Cui JZ, Cui Y, et al. Therapeutic effect of exogenous bone marrow-derived mesenchymal stem cell transplantation on silicosis via paracrine mechanisms in rats. Mol Med Rep. 2013;8:741–746.
   PubMed Web of Science ®Google Scholar
• Bandeira E, Oliveira H, Silva JD, et al. Therapeutic effects of adipose-tissue-derived mesenchymal stromal cells and their extracellular vesicles in experimental silicosis. Respir Res. 2018;19:104.
   PubMed Web of Science ®Google Scholar
• Phinney DG, Di Giuseppe M, Njah J, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat Commun. 2015;6:8472.
   PubMed Web of Science ®Google Scholar
• Morales MM, Souza SA, Loivos LP, et al. Pilot safety study of intrabronchial instillation of bone marrow-derived mononuclear cells in patients with silicosis. BMC Pulm Med. 2015;15:66.
   PubMed Web of Science ®Google Scholar